Literature DB >> 3234466

Cadralazine pharmacokinetics--a pilot study.

K Haglund1, R Dahlqvist, H Emilsson, G Englund.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3234466     DOI: 10.1007/bf00558256

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  High-performance liquid chromatographic determination of cadralazine in human plasma and urine.

Authors:  H Emilsson
Journal:  J Chromatogr       Date:  1988-01-22

2.  Human pharmacokinetics of cadralazine: a new vasodilator.

Authors:  S A Hauffe; J P Dubois; P R Imhof
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jul-Sep       Impact factor: 2.441

3.  Clinical evaluation of Dinamap 845 automated blood pressure recorder.

Authors:  J H Silas; A T Barker; L E Ramsay
Journal:  Br Heart J       Date:  1980-02

4.  Disposition and pharmacokinetics of cadralazine and individual metabolites in man.

Authors:  H Schütz; J W Faigle; W Küng; W Theobald
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

5.  Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug.

Authors:  C Semeraro; L Dorigotti; S Banfi; C Carpi
Journal:  J Cardiovasc Pharmacol       Date:  1981 May-Jun       Impact factor: 3.105

  5 in total
  2 in total

1.  Inhibition of complement components C3 and C4 by cadralazine and its active metabolite.

Authors:  M Andersson; A Hanson; G Englund; B Dahlbäck
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  D McTavish; R A Young; S P Clissold
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.